Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123
Sponsor: Asahi Kasei Pharma Corporation
This PHASE3 trial investigates Idiopathic Pulmonary Fibrosis and is currently completed. Asahi Kasei Pharma Corporation leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Aug 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE3
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asahi Kasei Pharma Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bunkyo, Japan , Chiba, Japan , Fukuoka, Japan , Hamamatsu, Japan , Himeji, Japan , Kamogawa, Japan , Kobe, Japan , Kumamoto, Japan , Kurashiki, Japan , Kurume, Japan and 16 more locations